VistaGen Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, VTGN, VistaGen Therapeutics Inc, priceseries

VistaGen Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
1.23
Close
1.20
High
1.26
Low
1.17
Previous Close
1.23
Daily Price Gain
-0.03
YTD High
2.11
YTD High Date
Jan 4, 2022
YTD Low
1.17
YTD Low Date
Mar 7, 2022
YTD Price Change
-0.89
YTD Gain
-42.58%
52 Week High
3.55
52 Week High Date
Jul 2, 2021
52 Week Low
1.17
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-0.90
52 Week Gain
-42.86%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 5. 2017
0.92
Dec 11. 2017
1.20
4 Trading Days
30.16%
Link
LONG
Aug 16. 2018
1.31
Sep 4. 2018
1.39
12 Trading Days
6.07%
Link
LONG
Sep 28. 2018
1.45
Oct 24. 2018
1.98
18 Trading Days
36.61%
Link
LONG
Aug 26. 2019
0.60
Sep 27. 2019
1.15
23 Trading Days
91.93%
Link
LONG
Oct 14. 2019
1.10
Oct 24. 2019
1.26
8 Trading Days
14.15%
Link
LONG
Dec 15. 2020
0.78
Jan 21. 2021
2.13
24 Trading Days
173.28%
Link
LONG
Feb 17. 2021
2.06
Feb 23. 2021
2.29
4 Trading Days
10.92%
Link
LONG
Apr 26. 2021
2.10
May 11. 2021
2.42
11 Trading Days
15.23%
Link
LONG
Jun 7. 2021
2.59
Jun 21. 2021
2.79
10 Trading Days
7.55%
Link
Company Information
Stock Symbol
VTGN
Exchange
NasdaqCM
Company URL
http://www.vistagen.com
Company Phone
650-577-3600
CEO
Shawn K. Singh
Headquarters
California
Business Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA 94080
Sector
-
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001411685
About

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system. Its product candidate, AV-101, is a next generation, orally available prodrug candidate in Phase 2 development, initially for the adjunctive treatment of Major Depressive Disorder in patients with an inadequate response to standard antidepressants. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Description

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing product candidates for patients with central nervous system (CNS) diseases. The company's lead product candidate, AV-101, which is in Phase IIa development as a augmentation option for adult patients suffering from treatment-resistant major depressive disorder (TRD). It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform, including drug rescue to develop proprietary small molecule new chemical entities (NCEs) for its internal drug candidate pipeline; and regenerative medicine (RM) using blood, cartilage, heart, and/or liver cells derived from hPSCs. In addition, the company offers CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. It has strategic collaborations with University Health Network, the McEwen Centre for Regenerative Medicine, and the Centre for the Commercialization of Regenerative Medicine for stem cell technology research, development, and cell production; and Norac Pharma, Pharmatek, and Synterys, Inc. to design, produce, and analyze AV-101 clinical trial materials and potential drug rescue NCEs. The company also has strategic relationships with Pharmaceutical Product Development, LLC; Cato Research, Ltd.; and Massachusetts General Hospital Clinical Trials Network and Institute for regulatory expertise and clinical development support. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading